Two injections, two different jobs

Comparing ChondroFiller injection and hyaluronic acid (HA) on duration of relief alone risks missing a more fundamental point: these two treatments are not doing the same job.

ChondroFiller is an acellular type-I collagen scaffold. Delivered as an ultrasound-guided outpatient injection, it gels within the joint and provides a structural matrix into which the patient's own progenitor cells can migrate. The aim is matrix-induced chondrogenesis — the body using the scaffold as a template to rebuild cartilage tissue within a focal defect. The treatment is targeting the damaged structure itself.

Hyaluronic acid works differently. As a viscosupplement, it temporarily restores the lubricating and shock-absorbing properties of synovial fluid, reducing friction and associated pain in a joint where the fluid has become thin or degraded. It does not regenerate cartilage tissue. Its benefit is symptomatic, addressing the biochemical environment of a broadly degenerative joint rather than repairing a discrete structural lesion.

In practical terms: ChondroFiller injection is suited to focal cartilage defects where structural repair is the goal; HA is suited to wider symptomatic osteoarthritis management. Both are given in clinic without surgery or general anaesthesia — but the mechanism, the target tissue, and the expected outcome pathway differ in ways that matter before any duration figures are considered.

Which patients each injection is designed for

Knowing which treatment is designed for your situation matters more than comparing their duration figures in the abstract.

ChondroFiller injection — for focal structural defects

The ChondroFiller injection is designed for patients with a discrete, focal cartilage lesion rather than generalised joint wear. Clinically, these are typically ICRS or Outerbridge Grade II–IV defects — areas where cartilage has been damaged, thinned, or lost — usually up to 3 cm² in size, though lesions up to 6 cm² can be within scope. The underlying cause is often traumatic (a sporting injury, an accident) or linked to a localised area of mechanical stress. These patients often have relatively preserved joint space elsewhere and a specific lesion that is, in principle, repairable.

Hyaluronic acid — for diffuse symptomatic osteoarthritis

HA viscosupplementation is suited to patients with broader, age-related joint degeneration — typically Kellgren–Lawrence Grade 1–3 osteoarthritis — where the primary problem is degraded synovial fluid and diffuse cartilage thinning across one or more compartments. There is no single repairable lesion; the goal is pain reduction and improved function rather than structural restoration.

The patient populations are not interchangeable

A 35-year-old with a post-traumatic cartilage defect on the medial femoral condyle and a 62-year-old with moderate tricompartmental OA are both reasonable candidates for an injection — but for fundamentally different treatments. Offering HA to the first patient addresses symptoms while leaving the structural problem unresolved; offering a regenerative scaffold to the second may not match the diffuse nature of the disease. Identifying which category applies is the clinical decision that determines whether duration figures become meaningful at all.

How long hyaluronic acid lasts — what the evidence shows

The evidence on how long HA lasts is unusually well characterised. A 2024 cross-sectional study of 105 patients (149 knees) asked patients to self-assess how long their last viscosupplementation had remained effective; the mean was 48.2 ± 24.8 weeks — roughly eleven months. That figure comes with meaningful variation depending on formulation and patient factors.

Formulation matters. A single-injection extended-release crosslinked HA (HANOX-M-XL) averaged 52.0 ± 24.7 weeks across 51 patients. Kellgren–Lawrence grade had a measurable effect: those with KL 1–2 disease averaged 62.6 weeks, compared with 48.9 weeks for KL 3–4 — a statistically significant difference (p=0.03). Male gender and older age were also independently associated with longer duration in that cohort.

What shortens the effect

Four factors independently predict shorter duration of benefit: BMI above 27.5 kg/m², multicompartmental knee involvement, more than three previous viscosupplementation cycles, and a sedentary lifestyle. Clinically, this means patients with more advanced or widespread disease — often those who have already had several rounds of HA — tend to get less time from each course.

On injection regimens

A systematic review of eleven studies found no consistent difference in outcomes between single and multiple injection schedules, and five-injection protocols were not superior to three-injection ones. A separate randomised study of 54 KL Grade II–III patients found that a single NASHA injection (Durolane®) produced significantly better WOMAC scores at week 26 and lower analgesic use compared with standard five-injection HA, and was more cost-effective. Single-injection crosslinked formulations are gaining traction partly for this reason.

The right frame for these numbers

The eleven-month mean and the KL-grade modifiers describe a well-evidenced, mature treatment with reliable expectations. What they measure, however, is pain and function — symptomatic relief. HA does not alter the structural state of the cartilage. Duration in this context means how long the lubrication effect persists, not how long a repair lasts. That distinction matters when reading the ChondroFiller evidence, where the outcome goals include the structural question as well.

ChondroFiller injection duration — what the data does and doesn't show

Published ChondroFiller outcomes tell a consistent story across multiple international centres — though one caveat matters for patients considering the injectable pathway at the London Cartilage Clinic.

Three peer-reviewed studies form the primary evidence base. The 2016 Schneider multicentre RCT (n=13 in the ChondroFiller group) showed statistically significant IKDC score improvements at 3 and 6 months, maintained at 12 months, alongside MRI MOCART scores reflecting progressive cartilage maturation and no adverse events. A 2024 series (Simeonov, n=17, mean age 31) confirmed significant Lysholm and IKDC gains at 3, 6, and 12 months, with scores plateauing stably between the 6- and 12-month assessments. Across international centres, published headline data report a mean improvement of approximately +30 IKDC points in the knee and MOCART scores of 70–87, accumulated over more than 19,000 cases globally.

The surgical–injectable distinction

Every one of those studies used arthroscopic surgical delivery. The current UK service, delivered at the London Cartilage Clinic on Harley Street, works differently: ultrasound-guided outpatient injection, with the collagen scaffold introduced into the joint as a protective cushion over degenerated surfaces rather than filling a surgically prepared defect from below. No peer-reviewed duration data specific to this injectable route has yet been published — a straightforward limitation of a newer delivery method still building its evidence base.

What the protocol tells us in the interim

Clinical protocol guidance for the injectable pathway calls for bi-annual top-up injections within a structured maintenance programme. In practical terms, patients should expect a return visit roughly every two years rather than a single one-off procedure: ongoing maintenance is built into the design of the programme from the outset.

Safety and the broader evidence base

The surgical studies do firmly establish the product's regenerative mechanism and safety profile. A 2025 ex vivo model found a 2.4-fold increase in DNA content at day 14 with ChondroFiller versus untreated defect controls, supporting the scaffold's ability to recruit endogenous progenitor cells. For injectable-specific duration data, the evidence remains at an early stage; for the underlying biology and safety of the product itself, it is considerably more mature.

Why no direct comparison exists — and what that means for decision-making

No published head-to-head randomised trial comparing ChondroFiller injection against hyaluronic acid for duration of knee pain relief currently exists — and understanding why that gap exists is more instructive than lamenting it.

The structural obstacle is that 'duration of relief' is a category that fits HA neatly and fits ChondroFiller only partially. For HA, relief is the outcome: the treatment delivers lubrication and symptom attenuation, and the question of how long that effect persists is both coherent and measurable. For the ChondroFiller injection, relief is a consequence of something else — scaffold-supported matrix-induced chondrogenesis — and the deeper outcome goal is structural. Measuring the two treatments on the same duration axis is a little like judging a physiotherapy programme and a splint by how quickly they reduce pain on day one: the number is real, but it misrepresents what one of the interventions is trying to do.

There is also a target-population mismatch. HA is indicated for symptomatic degeneration across a compartment; ChondroFiller injection is designed for a focal repairable lesion. A patient with diffuse OA receiving HA and a patient with a discrete ICRS Grade III defect receiving ChondroFiller injection are not comparable subjects, so a trial that enrolled both interchangeably would answer a question that clinicians do not actually face.

For HA, the practical implication of the evidence gap is limited — its duration profile is mature and well-characterised. For the injectable ChondroFiller pathway specifically, peer-reviewed duration data remain at an early stage; the protocol-based maintenance schedule represents informed clinical guidance rather than a published outcome benchmark.

The comparison that matters in practice is not ChondroFiller versus HA on a duration leaderboard but whether a given patient's joint pathology calls for structural repair or symptomatic support — two questions that require imaging and clinical assessment, not product comparison.

How to decide — and getting assessed in London

The single most useful question a patient can bring to a consultation is not 'which injection lasts longer?' but 'do I have a focal cartilage lesion or diffuse joint wear?' — because the answer determines whether structural repair is even in scope.

That distinction is often invisible on a plain weight-bearing X-ray, which remains the first investigation most GPs order. Focal chondral defects of the kind suited to the ChondroFiller injection — a discrete lesion with repairable margins — typically only show on MRI. A patient who has had X-rays alone may carry an incomplete diagnosis: their imaging rules out gross bone-on-bone disease but does not confirm whether a repairable focal lesion exists. If MRI identifies one, the ChondroFiller injection — an ultrasound-guided outpatient procedure — becomes a candidate treatment targeting that defect directly. If imaging reveals diffuse compartmental wear without a discrete lesion, HA and other symptom-management pathways are the more appropriate discussion.

Liquid Cartilage™ / ChondroFiller injection is available in the UK at the London Cartilage Clinic on Harley Street, where Professor Paul Y. F. Lee leads its delivery. Patients can book a specialist assessment — including review of existing imaging — at londoncartilage.com.

1. [1] Implantation of ChondroFiller Liquid® as a scaffold material for the treatment of chondral lesions of the knee joint. (2024). https://doi.org/10.5272/jimab.2024304.5936 https://doi.org/10.5272/jimab.2024304.5936
2. [2] Controlled, randomized multicenter study to compare compatibility and safety of ChondroFiller liquid with microfracturing. (2016). https://doi.org/10.5348/VNP05-2016-1-OA-1 https://doi.org/10.5348/VNP05-2016-1-OA-1
3. [3] A Cross-Sectional Study of Factors Predicting the Duration of the Efficacy of Viscosupplementation in Knee Osteoarthritis. (2024). https://doi.org/10.3390/jcm13071949 https://doi.org/10.3390/jcm13071949
4. [4] The Association between Radiographic Features and the Duration of Effectiveness of a Single Injection of Extended-Release Hyaluronic Acid (HANOX-M-XL) in Patients with Knee Osteoarthritis. (2022). https://doi.org/10.1177/19476035221109230 https://doi.org/10.1177/19476035221109230
5. [5] Knee Viscosupplementation: Cost-Effectiveness Analysis between Stabilized Hyaluronic Acid in a Single Injection versus Five Injections of Standard Hyaluronic Acid. (2017). https://doi.org/10.3390/ijms18030658 https://doi.org/10.3390/ijms18030658
6. [6] Development of an Ex Vivo Osteochondral Biomimetic Platform for Mechanistic Investigation of Cartilage Regeneration. (2025). https://doi.org/10.3390/ijms262311759 https://doi.org/10.3390/ijms262311759
7. [7] Joint Preservation in Patients with Grade IV Osteoarthritis of the Knee: Use of an Acellular Collagen Scaffold (ChondroFiller® Liquid) and Blood Derived Stem Cell Rich Graft – A Prospective Controlled Trial. (2025). https://doi.org/10.29011/2575-9760.011360 https://doi.org/10.29011/2575-9760.011360